英国政府开始调查葛兰素史克

    英国药业巨头葛兰素史克（GlaxoSmithKline）正在接受英国反严重欺诈办公室（Serious Fraud Office，SFO）对其商业行为的调查。

    这家公司自称坚持“最高的道德标准”，并将“全力配合”政府调查。反严重欺诈办公室在一份声明中写道：“反严重欺诈办公室主任已经开始对葛兰素史克及其子公司的商业行为展开刑事调查。”但这份声明没有详细说明这家公司非法活动的性质。

    本月早些时候，中国执法部门指控葛兰素史克贿赂医院和政府官员。当时，中国官方指控葛兰素史克前中国区负责人马克锐在中国建立了“庞大的贿赂网络”。

    针对上述指控，葛兰素史克在声明中回应称：“我们非常认真地对待中方提出的指控。我们对这些指控深表关切，这种行为违反了葛兰素史克的价值。我们将继续全力配合相关部门对该事件进行调查。”

    BBC4月份报道称，在波兰，11名医生和这家制药公司的一名区域经理因为2010年至2012年期间的腐败行为而遭到了指控。

    据BBC报道，如果最近的指控属实，那么，这家公司可能已经违反了英国《反贿赂法》（UK Bribery Act）和美国《反海外腐败法》（US Foreign Corrupt Practices Act）。

    目前尚无其他详细信息。葛兰素史克发言人也拒绝就此发表评论。（财富中文网）

    译者：刘进龙/汪皓

    GlaxoSmithKline (GSK), the British pharmaceutical giant, is under investigation by the UK's Serious Fraud Office (SFO) over its commercial practices.

    According to the company, it intends to uphold the "highest ethical standards" and will "cooperate fully" with the government inquiry. In a statement, the SFO wrote, "The Director of the SFO has opened a criminal investigation into the commercial practices of GlaxoSmithKline plc and its subsidiaries." It did not elaborate any further about the nature of any illegal activity by the company.

    Earlier this month, Chinese law enforcement accused GlaxoSmithKline of bribing hospital and government officials. At that time, Chinese authorities said GlaxoSmithKline's former China chief Mark Reilly was responsible for starting a "massive bribery network" in the country.

    In response to those accusations, GlaxoSmithKline said in a statement: "We take the allegations that have been raised very seriously. They are deeply concerning to us and contrary to the values of GlaxoSmithKline. We will continue to fully co-operate with the authorities in this matter."

    In Poland, meanwhile, 11 doctors and a regional manager for the pharmaceutical company were charged with corruption from 2010 to 2012, according to the BBC in April.

    If the latest allegations prove true, the company may have violated the UK Bribery Act and the US Foreign Corrupt Practices Act, according to the BBC.

    No other details were immediately available. A spokeswoman for GlaxoSmithKline declined to comment.